These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9619690)

  • 1. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder.
    Koran LM; Pallanti S; Paiva RS; Quercioli L
    Eur Neuropsychopharmacol; 1998 May; 8(2):121-6. PubMed ID: 9619690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Ward H; Shapira NA; Sallee FR; Gamel N; Elliott M
    J Clin Psychopharmacol; 2006 Feb; 26(1):79-83. PubMed ID: 16415712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.
    Koran LM; Sallee FR; Pallanti S
    Am J Psychiatry; 1997 Mar; 154(3):396-401. PubMed ID: 9054789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.
    Karameh WK; Khani M
    Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26221004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
    López-Ibor JJ; Saiz J; Cottraux J; Note I; Viñas R; Bourgeois M; Hernández M; Gómez-Pérez JC
    Eur Neuropsychopharmacol; 1996 May; 6(2):111-8. PubMed ID: 8791036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up study of patients with refractory obsessive-compulsive disorder.
    Ross S; Fallon BA; Petkova E; Feinstein S; Liebowitz MR
    J Neuropsychiatry Clin Neurosci; 2008; 20(4):450-7. PubMed ID: 19196930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
    Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melasma: A rare adverse effect of clomipramine.
    Kar SK
    Indian J Pharmacol; 2016; 48(4):453-454. PubMed ID: 27756961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
    Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
    Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response versus remission in obsessive-compulsive disorder.
    Simpson HB; Huppert JD; Petkova E; Foa EB; Liebowitz MR
    J Clin Psychiatry; 2006 Feb; 67(2):269-76. PubMed ID: 16566623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.
    Fallon BA; Liebowitz MR; Campeas R; Schneier FR; Marshall R; Davies S; Goetz D; Klein DF
    Arch Gen Psychiatry; 1998 Oct; 55(10):918-24. PubMed ID: 9783563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.
    DeVeaugh-Geiss J; Katz R; Landau P; Goodman W; Rasmussen S
    Psychopharmacol Bull; 1990; 26(1):54-9. PubMed ID: 2196627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents.
    Figueroa Y; Rosenberg DR; Birmaher B; Keshavan MS
    J Child Adolesc Psychopharmacol; 1998; 8(1):61-7. PubMed ID: 9639080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated thyroid indices in children and adolescents with obsessive-compulsive disorder: effects of clomipramine treatment.
    McCracken JT; Hanna GL
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):581-7. PubMed ID: 16190790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Mundo E; Maina G; Uslenghi C
    Int Clin Psychopharmacol; 2000 Mar; 15(2):69-76. PubMed ID: 10759337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clomipramine-induced tourettism in obsessive-compulsive disorder: clinical and theoretical implications.
    Moshe K; Iulian I; Seth K; Eli L; Joseph Z
    Clin Neuropharmacol; 1994 Aug; 17(4):338-43. PubMed ID: 9316681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of obsessive-compulsive disorder.
    Klein DF
    Encephale; 1990; 16 Spec No():331-4. PubMed ID: 2209491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
    Pato MT; Hill JL; Murphy DL
    Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial.
    DeVeaugh-Geiss J; Moroz G; Biederman J; Cantwell D; Fontaine R; Greist JH; Reichler R; Katz R; Landau P
    J Am Acad Child Adolesc Psychiatry; 1992 Jan; 31(1):45-9. PubMed ID: 1537780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.
    Foa EB; Liebowitz MR; Kozak MJ; Davies S; Campeas R; Franklin ME; Huppert JD; Kjernisted K; Rowan V; Schmidt AB; Simpson HB; Tu X
    Am J Psychiatry; 2005 Jan; 162(1):151-61. PubMed ID: 15625214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.